Driving innovation in Cardiovascular therapeutics

Over the last 100 years the death rate from cardiovascular disease (CVD) has been cut in half, in part due to scientific discoveries including the powerful link between nutrition and exercise and heart health, interventions rapidly addressing coronary blood flow and the development of drugs for managing blood pressure, cholesterol levels, blood sugar/diabetes and anticoagulation.

Arnaud Bastien, MD, vice president and global program lead, early and late development, cardiovascular and neuroscience at Bristol Myers Squibb, offers insights on hypertrophic cardiomyopathy (HCM), discusses why cardiovascular diseases — such as HCM — are a priority area of study for BMS and how the team is revolutionizing treatment advancements for patients.

Many of us are familiar with important principles of improving cardiovascular health – eating a heart healthy diet, managing stress, getting regular exercise and knowing your cardiovascular risk numbers. But did you know that up to 1 in 200 people are living with a serious and frequently misdiagnosed cardiovascular condition called Hypertrophic Cardiomyopathy (HCM)?